BR112018009653A2 - produção de proteínas recombinantes n-deglicosiladas in vivo por co-expressão com endo h - Google Patents

produção de proteínas recombinantes n-deglicosiladas in vivo por co-expressão com endo h

Info

Publication number
BR112018009653A2
BR112018009653A2 BR112018009653A BR112018009653A BR112018009653A2 BR 112018009653 A2 BR112018009653 A2 BR 112018009653A2 BR 112018009653 A BR112018009653 A BR 112018009653A BR 112018009653 A BR112018009653 A BR 112018009653A BR 112018009653 A2 BR112018009653 A2 BR 112018009653A2
Authority
BR
Brazil
Prior art keywords
proteins
plants
expression
production
vivo
Prior art date
Application number
BR112018009653A
Other languages
English (en)
Inventor
Mammedov Tarlan
Original Assignee
Mammedov Tarlan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mammedov Tarlan filed Critical Mammedov Tarlan
Publication of BR112018009653A2 publication Critical patent/BR112018009653A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

plantas têm surgido como um sistema de expressão alternativo e têm sido cada vez mais utilizadas pela indústria e comunidade acadêmica para a produção de proteínas alvo. contudo, a habilidade de plantas para glicosilar proteínas pode ser uma limitação considerável para aquelas proteínas que não necessitam de n-glicolisação. por exemplo, proteínas de plasmodium falciparum ou uma cadeia a do fator humano xii não portam glicanos ligados ao n, assim como o antígeno protetor (pa) de bacillus anthracis não porta uma glicoproteína; entretanto, essas proteínas contêm potenciais locais de glicosilação por ligação ao n que podem ser aberrantemente glicosilados durante a expressão em leveduras, em mamíferos ou sistemas de plantas, levando potencialmente a uma funcionalidade e imunogenicidade reduzidas por conta de enovelamento incorreto/alterado e/ou mascaramento de epítopos. para superar esse problema, foi desenvolvida recentemente uma estratégia de deglicosilação enzimática de proteínas in vivo por co-expressão com pngase f (peptídeo: n-glicosidase f) com o uso de expressão transiente em plantas (wipo pedido de patente wo/2012/170678), que permitiu a produção do candidato à vacina contra malária pfs48/45, que pode fornecer uma alta atividade de bloqueio de transmissão (tb) (mamedov et al., 2012). adicionalmente, outros antígenos deglicosilados induziram significativamente altos níveis de respostas de anticorpos neutralizantes de toxinas em ratos em comparação com formas glicosiladas (mamedov et al, manuscrito anexado). apesar de um tratamento pngase f (deglicosilação in vivo) remover oligossacarídeo intacto, também causa mudança no aminoácido na proteína deglicosilada devido à desaminação da asparagina (n) no local nxs/t (sequência) em um aspartato (d). nesse estudo, uma estratégia foi desenvolvida para produção de proteínas alvo em plantas em formas não n-glicosiladas, mas sem nenhuma mudança de aminoácido no local nxs/t das proteínas deglicosiladas resultantes, as quais podem fornecer produção de proteínas recombinantes não n-glicosiladas em plantas ou outro sistema eucariótico com enovelamento como o nativo. portanto, materiais e métodos para de-glicosilação in vivo de proteínas n-glicosiladas recombinantes por co-expressão com endo-n-acetil-ß-glicosaminidase h (endo h) em plantas, com o uso de um sistema de expressão transiente, são descritos nesta invenção. um método para expressar ativamente endo h em plantas também é fornecido.
BR112018009653A 2015-11-13 2015-11-13 produção de proteínas recombinantes n-deglicosiladas in vivo por co-expressão com endo h BR112018009653A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2015/058781 WO2017081520A1 (en) 2015-11-13 2015-11-13 Production of in vivo n-deglycosylated recombinant proteins by co-expression with endo h

Publications (1)

Publication Number Publication Date
BR112018009653A2 true BR112018009653A2 (pt) 2018-11-13

Family

ID=55085689

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018009653A BR112018009653A2 (pt) 2015-11-13 2015-11-13 produção de proteínas recombinantes n-deglicosiladas in vivo por co-expressão com endo h

Country Status (11)

Country Link
US (1) US11041163B2 (pt)
EP (1) EP3374500A1 (pt)
JP (1) JP2019504638A (pt)
CN (1) CN108463550A (pt)
AU (1) AU2015414199A1 (pt)
BR (1) BR112018009653A2 (pt)
CA (1) CA3005304C (pt)
IL (1) IL259301B2 (pt)
MX (1) MX2018006001A (pt)
RU (1) RU2741347C2 (pt)
WO (1) WO2017081520A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020013774A1 (en) 2018-07-12 2020-01-16 Akdeniz Universitesi In vivo post-translational processing of target proteins by furin in plants: engineering, expression and production of functional active human furin in n. benthamiana plants
CN113557241A (zh) * 2019-03-12 2021-10-26 比贝婷作物科学有限公司 大麻素前体的生产
WO2022115083A1 (en) * 2020-11-24 2022-06-02 Akdeniz Universitesi Engineering, production and characterization of plant produced, soluble human angiotensin converting enzyme-2 as a therapeutic target in covid-19
EP4029569A1 (en) 2020-12-02 2022-07-20 Mammedov, Tarlan Engineering, production and characterization of plant produced nucleocapsid and spike structural proteins of sars-cov-2 as vaccine candidates against covid-19

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036752A2 (en) 2000-11-06 2002-05-10 Chr. Hansen A/S Method of producing non-bovine chymosin and use thereof
CA2443781A1 (en) 2001-04-24 2002-10-31 Innogenetics N.V. Core-glycosylated hcv envelope proteins
US6720165B2 (en) * 2001-06-14 2004-04-13 Zyomix, Inc. Methods for making antibody fragments and compositions resulting therefrom
US11673926B2 (en) * 2011-06-07 2023-06-13 Ibio, Inc. In vivo de-glycosylation of recombinant proteins by co-expression with PNGase F
CN104487571A (zh) 2012-02-07 2015-04-01 丹尼斯科美国公司 糖基化作为植酸酶的稳定剂
US8940294B2 (en) 2012-03-02 2015-01-27 Tissuetech, Inc. Methods of isolating and culturing stem cells
WO2015080603A1 (en) 2013-11-28 2015-06-04 Antony John Fairbanks Glycoproteins
US9689016B2 (en) 2013-12-18 2017-06-27 Caliber Biotherapeutics, Llc Method for in vivo production of deglycosylated recombinant proteins used as substrate for downstream protein glycoremodeling

Also Published As

Publication number Publication date
CN108463550A (zh) 2018-08-28
US11041163B2 (en) 2021-06-22
US20180327764A1 (en) 2018-11-15
AU2015414199A2 (en) 2018-07-05
RU2018117921A (ru) 2019-12-16
WO2017081520A1 (en) 2017-05-18
JP2019504638A (ja) 2019-02-21
IL259301B2 (en) 2023-07-01
MX2018006001A (es) 2018-09-17
IL259301B1 (en) 2023-03-01
CA3005304A1 (en) 2017-05-18
RU2018117921A3 (pt) 2019-12-16
RU2741347C2 (ru) 2021-01-25
EP3374500A1 (en) 2018-09-19
CA3005304C (en) 2024-02-20
AU2015414199A1 (en) 2018-06-14
IL259301A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
BR112018009653A2 (pt) produção de proteínas recombinantes n-deglicosiladas in vivo por co-expressão com endo h
Ellebedy et al. Re-engaging cross-reactive memory B cells: the influenza puzzle
BRPI1015917A2 (pt) antígenos de rsv recombinantes.
WO2017181452A8 (zh) Glp-1r/gcgr双靶点激动剂多肽治疗脂肪肝病、高脂血症和动脉硬化
BR112017019170A2 (pt) métodos para o tratamento de doença do fígado gorduroso não alcoólico e / ou lipodistrofia
CL2018002826A1 (es) Proteínas f de prefusión del virus respiratorio sincicial (vrs) solubles y estabilizadas
BR112017010094A2 (pt) anticorpos compreendendo regiões constantes de cadeias pesadas modificadas
BR112017006178A2 (pt) região fc, anticorpos, formulação farmacêutica e usos dos anticorpos
BR112012022688A2 (pt) proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão
BR112016007868A2 (pt) vacinas contra o vírus de epstein-barr
WO2016057769A3 (en) Glycoengineered antibody drug conjugates
AR061894A1 (es) Vacunas para malaria
WO2007132480A3 (en) A composition useful as a vaccine
GT201200271A (es) Proteínas que se unen al tnf-a
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
BR112015023507A2 (pt) vacina estável líquida, e, métodos para vacinar um bovino e para produzir uma vacina estável líquida
PE20190110A1 (es) Proteinas f de prefusion del vrs estabilizadas
BR112015026709A8 (pt) instrumento médico de prova para alinhamento de um componente acetabular, sistema para alinhamento e implantação, instrumento médico de um formato fixo e métodos de alinhamento e implantação
BR112018007960A2 (pt) conjugado, proteína pcrv, composição imunogênica, métodos de preparação de uma composição imunogênica, de tratamento e de produção de um bioconjugado, polinucleotídeo, vetor, célula hospedeira, e, bioconjugado.
HRP20201651T1 (hr) Uporaba cd24 za snižavanje razina lipoproteina niske gustoće kolesterola
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
EA201391200A1 (ru) Способы и композиции для вакцинации от staphylococcus aureus
WO2018091729A3 (en) Aqueous pharmaceutical formulations
BR112017002496A2 (pt) agente de controle contra a síndrome reprodutiva e respiratória porcina
Bommireddy et al. Influenza virus-like particle-based hybrid vaccine containing RBD induces immunity against influenza and SARS-CoV-2 viruses

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements